<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400150</url>
  </required_header>
  <id_info>
    <org_study_id>BP-007</org_study_id>
    <nct_id>NCT03400150</nct_id>
  </id_info>
  <brief_title>ProSpace™ Balloon System Pivotal Study BP-007</brief_title>
  <official_title>CLINICAL PROTOCOL for the INVESTIGATION Of the ProSpace™ Balloon System Pivotal Study BP-007</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioProtect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioProtect</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ProSpace™ System is intended to temporarily position the anterior rectal wall away from
      the prostate during radiotherapy for prostate cancer and in creating this space it is the
      intent of the ProSpace System to reduce the radiation dose delivered to the anterior rectum.
      ProSpace is a balloon composed of a biodegradable material that maintains that space for the
      entire course of prostate radiotherapy treatment and is completely absorbed by the patient's
      body over time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a prospective, multi-center, randomized, double-arm, single blind,
      concurrently controlled study to assess the safety and efficacy of the ProSpace Balloon in
      prostate cancer subjects undergoing radiotherapy by means of intensity modulation radiation
      therapy (IMRT).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized in a 2:1 ratio (ProSpace implantation:control)</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Study subjects are blinded to group assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event Rate of Occurrence</measure>
    <time_frame>Duration of at least 2 days through 6 months</time_frame>
    <description>Rate of occurrence of Grade 1 or greater rectal adverse events and implantation procedure related adverse events through 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in Rectal Radiation Exposure</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of at least 25% of the volume of the rectum receiving greater or equal to 70 Gy (VRectum70) when compared to pre-implantation values.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ProSpace group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Marking + ProSpace implantation + IMRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Marking + IMRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ProSpace</intervention_name>
    <description>ProSpace balloon implantation</description>
    <arm_group_label>ProSpace group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Control - Marking &amp; IMRT are standard of care for prostate cancer - there is no study-specific intervention</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age

          -  Have been histologically diagnosed with invasive adenocarcinoma of the prostate, at
             clinical stage T1-T3 (as determined by a biopsy taken within 9 months of the screening
             visit)

          -  Be scheduled for radiation therapy (XRT) by means of IMRT

        Exclusion Criteria:

          -  Any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject
             has been disease free for a minimum of 5 years

          -  Prior radical prostatectomy

          -  Prior cryosurgery or radiotherapy for prostate cancer, or other local therapy for
             prostate cancer

          -  Prior radiotherapy to the pelvis, including brachytherapy

          -  History of prior surgery involving the rectum or anus

          -  Prior surgical procedure involving the peri-rectal and/or peri-prostatic area
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joyce Dunsmore</last_name>
    <phone>703-628-8603</phone>
    <email>joyce@bioprotect.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Western Radiation Oncology</name>
      <address>
        <city>Apple Valley</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Woltz</last_name>
      <phone>650-485-9904</phone>
      <email>woltzjn@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KSK Medical Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Tokita, MD</last_name>
      <phone>949-417-1100</phone>
      <email>LBarnes@ccoi.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Institute</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonelle Morsley</last_name>
      <phone>386-239-8535</phone>
      <email>jonelle.horsley@auihealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamza Hasan</last_name>
      <phone>410-955-8652</phone>
      <email>hhasan2@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <zip>21117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Hudes, MD</last_name>
      <phone>443-231-1203</phone>
      <email>rbennett@chesuro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology Nevada</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kos, MD</last_name>
      <phone>775-850-6505</phone>
      <email>amoliga@urologynevada.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Center of New York</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Blanco</last_name>
      <phone>516-394-9600</phone>
      <email>jblanco@imppllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Brisendine</last_name>
      <phone>843-792-9007</phone>
      <email>brisend@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assuta Ashdod</name>
      <address>
        <city>Ashdod</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yewgeniya Vitkin</last_name>
      <phone>972-72-3398279</phone>
      <email>yewgeniyavi@assuta.co.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yarra Barr</last_name>
      <email>yaaraba1@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastro</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelin van der Peet</last_name>
      <phone>31884455874</phone>
      <email>Evelien.vanderPeet@maastro.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Maria Skłodowska-Oncology Centre</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pitor Saniewski</last_name>
      <email>p.saniewski@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CUF Porto Instituto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulo Costa</last_name>
      <phone>+351-22 00 34 001</phone>
      <email>Luis.Rosa@jmellosaude.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine MacLeod</last_name>
      <email>Elaine.MacLeod2@ggc.scot.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bioprotect.com</url>
    <description>Company website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

